SAS Output

18-JUN-2019 6:10

MELAN ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1320-Adv, BRAF mut, Inter v Contin 1 N 1 Lead-in Continuous Dosing 248 249 31 14 6 0 0 09/19/2014 232 96
            249 31 14 6 0 0      
 
    2 Y 2 Continuous Dosing 216 108 17 11 6 4 1 09/19/2014    
        3 Intermittent Dosing   103 16 12 5 1 0      
            211 33 23 11 5 1      
 
  S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro) 1 Y 1 MK-3475 (pembrolizumab) 77 25 14 7 4 0 0 02/06/2017 112 50
            25 14 7 4 0 0      
 
  S1607-MELAN, Adv, T-VEC, MK-3475 1 Y 1 T-VEC + MK-3475(pembrolizumab) 64 18 17 10 5 1 0 06/05/2018 69 26
            18 17 10 5 1 0      
 
  S1616-MELAN, Adv, Ipilimumab Nivolumab 1 Y 1 Ipilimumab 94 12 8 4 3 2 0 10/23/2017 222 91
        2 Nivolumab + Ipilimumab   31 21 11 6 2 1      
            43 29 15 9 4 1      
 
  S1801-Melan, Adv, Adj vs Neoadj Pembrolizumab 1 Y 1 Adjuvant Arm 556 12 12 12 10 7 0 02/15/2019 269 102
        2 Neoadjuvant Pembrolizumab   9 9 9 9 4 1      
            21 21 21 19 11 1      
 
    2 Y 3 Surgery 556 11 11 11 9 7 0 02/15/2019    
            11 11 11 9 7 0      
 
    3 Y 4 Post-Surgery Pembro 556 2 2 2 1 1 0 02/15/2019    
            2 2 2 1 1 0      
 
Yes EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T 1 E Total Registrations   38 12 8 3 1 0 11/03/2015 363 144
            38 12 8 3 1 0      
 
    2 E Total Registrations   14 7 2 2 0 0 11/03/2015    
            14 7 2 2 0 0      
 
  EA6141-Melan, Avd, Nivolumab+Ipi Sargmostim 1 E Total Registrations   36 0 0 0 0 0 03/25/2016 221 93
            36 0 0 0 0 0      
 
No EA6174-Merkel, Adjuvant Pembrolizumab vs Observation 1 E Total Registrations   1 1 1 1 0 0 05/01/2019 58 24
            1 1 1 1 0 0